Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA safety study for fluorescence-guided brain tumor resection in children and adolescents
NL-OMON60505Phase 2Completed
- Sponsor
- Universität Münster
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in brain neoplasm, sponsored by Universität Münster. Primary endpoint: Incidence of severe adverse events. Started Oct 2022; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
brain neoplasm
Beyond the preview
Go deeper on NL-OMON60505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60505.